With pharmaceutical markets expanding globally and commercial strategies shifting to a more complex portfolio and access-focused models- the nature of the global pharmaceutical market is changing.
Not only pharmaceutical companies need to maintain balanced pipelines and partnerships that sustain their current commercial performance, but they also need to ensure their ability to capitalise on the opportunities of the growing emerging markets.